Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial

Published 2016 View Full Article

Authors

Keywords

Daclizumab high-yield process, Relapsing and remitting multiple sclerosis, MS-specific health-related quality of life measures, Multiple Sclerosis Impact Scale

Journal

Multiple Sclerosis and Related Disorders

Volume 6, Issue -, Pages 66-72

Publisher

Elsevier BV

Online

2016-02-02

DOI

10.1016/j.msard.2016.02.001

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started